Phase II Trial of Doxorubicin/Docetaxel/Cyclophosphamide for Locally Advanced and Metastatic Breast Cancer: Results from NSABP Trial BP-58
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference31 articles.
1. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines;Gianni;J Natl Cancer Inst,1995
2. Paclitaxel as second and subsequent chemotherapy for metastatic breast cancer: activity independent of prior anthracycline response;Seidman;J Clin Oncol,1995
3. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion;Wilson;J Clin Oncol,1994
4. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer;Ravdin;J Clin Oncol,1995
5. A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group;Ten Bokkel Huinink;Ann Oncol,1994
Cited by 22 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Microtubule Inhibitors;Holland‐Frei Cancer Medicine;2023-02-20
2. Chemotherapeutic Protocols for the Treatment of Breast Cancer;Chemotherapy Protocols and Infusion Sequence;2022
3. A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy;Investigational New Drugs;2019-11-15
4. Chemotherapy-Induced Cognitive Impairment Is Associated with Cytokine Dysregulation and Disruptions in Neuroplasticity;Molecular Neurobiology;2018-07-14
5. Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study;Supportive Care in Cancer;2018-03-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3